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Cleft Lip and/or Palate in Infants
Prenatally Exposed to Opioids
Kerry Proctor-Williams, PhD, CCC-SLP1
and Brenda Louw, DPhil, SLP1
Abstract
Objective: To determine the prevalence and odds ratios for cleft lip and/or palate (CL/P) among infants prenatally exposed to
opioids with or without neonatal opioid withdrawal syndrome (NOWS).
Design: This study represents an exploratory, retrospective cohort study design of newborn medical health records from 2011 to
2016.
Setting: Records were drawn from a regional health system located in South Central Appalachia.
Population and Study Sample: The original population yielded 3 cohorts of infants: (1) infants with opioid exposure (OE) but not
requiring pharmacological intervention (OE; N¼ 168); (2) infants with NOWS requiring pharmacological intervention (N¼ 294);
and (3) infants with no opioid exposure (NOE; N ¼ 16 090), the primary comparison group.
Main Outcome: Infants in the NOWS and OE groups showed significantly increased prevalence and odds ratios for CL/P when
compared to those in the NOE group.
Results: Prevalence rates per 1000 live births for infants with OE (35.71) and infants with NOWS (6.80) were significantly higher
than those for infants with NOE (1.37). Comparison of infants with OE to the NOE group revealed significantly increased odds for
CL/P, isolated cleft palate (CP), cleft lip (CL), and cleft lip and palate (CLP) (27.05, 41.81, 19.26, 19.37, respectively; all Ps < .008).
The odds ratios for infants with NOWS compared to the NOE group were significantly higher for CL/P and CP (5.00 and 10.98,
respectively; Ps < .03) but not for CL and CLP.
Conclusion: The results provide additional evidence that prenatal OE should be considered among the critical environmental risk
factors that can contribute to CL/P.
Keywords
epidemiology, hard palate, fetal development, palatal development, prenatal development, soft palate, etiology, drug use
Introduction
The United States is experiencing an opioid crisis which has
important implications for cleft care. Among those caught in
this epidemic are pregnant women, putting their unborn and
newborn babies at immediate health risk and at later long-term
risk for adverse neurodevelopmental and academic outcomes
(Oei et al., 2017; Fill et al., 2018; Benninger et al., 2020). As a
result, the serious public health problem of prescription drug
use, misuse, and abuse in the United States is emerging as a
possible new environmental risk factor for cleft lip and/or
palate (CL/P).
Based on the 2015 National Survey on Drug Use and Health
(NUSDUH), approximately 91.8 million Americans adults
used opioids, 11.5 million illicitly used or misused opioid pain
relievers, 0.8 million used heroin, and 1.9 had an opioid use
disorder (Wu et al., 2016; Han et al., 2017). Furthermore, there
may be an additional 2.5 million or more individuals not
included in the NUSDUH survey who receive legitimate opioid
prescriptions but have an opioid use disorder nonetheless
(Kolodny et al., 2015).
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Over the last decade, prescribed use of opioids such as mor-
phine, hydrocodone, and oxycodone for pain during pregnancy
has increased substantially (Bateman et al., 2014; McQueen
and Murphy-Oikenen, 2016). Several large-scale studies have
found that more than 20% of women fill a prescription for a
schedule C pain reliever during pregnancy, even following the
addition of warning labels on boxes (Yang et al., 2008; Desai
et al., 2014; Raval et al., 2014). Women’s illicit use of opioids
further adds to the risk of prenatal exposure to the fetus.
Prenatal exposure to opioids and other drugs can have
immediate and serious consequences for newborns. For about
half of all prenatally drug exposed newborns, this includes a
condition now called neonatal opioid withdrawal syndrome
(NOWS) by federal agencies such as the US Food and Drug
Administration (Jones et al., 2010; Patrick et al., 2020). It was
previously called Neonatal Abstinence Syndrome, or NAS,
which included withdrawal from drugs other than opioids as
well (Patrick et al., 2020). Neonatal opioid withdrawal syn-
drome includes a constellation of physiological and behavioral
characteristics that occur in a newborn infant because of the
sudden systemic withdrawal at birth from the drugs, usually
opioids, which the mother used during pregnancy (Finnegan
et al., 1975; Kocherlakota, 2014; Barfield, 2016). It is impor-
tant to note that not all prenatally drug exposed infants expe-
rience NOWS, but many do experience some withdrawal
symptoms and are at-risk, nonetheless.
Accordingly, it does not come as much of a surprise that
along with the increasing rates of opioid use during pregnancy,
rates of NOWS have also dramatically increased (Davies et al.,
2016). Between 2000 and 2009, the incidence of NOWS in the
United States increased more than 300%. By 2012, the inci-
dence of NOWS was 5.8 cases per 1000 births and prevalence
was 30% to 50% of prenatally opioid exposed infants. Thus,
about every 15 minutes in the United States a baby is born who
experiences opioid withdrawal and every hour a baby is diag-
nosed with NOWS (Centers for Disease Control and Preven-
tion, 2013; Patrick et al., 2015; Ko et al., 2016; National
Institute on Drug Abuse, 2016; 2019).
Opioids as Teratogens for CL/P
According to Lind et al. (2017), the potential teratogenic
effects of opioids during pregnancy are an area of great public
health concern given that congenital disorders are serious,
often costly, and can cause lifelong challenges. Broussard
et al. (2011) and Yazdy et al. (2015) linked opioid use during
pregnancy to congenital malformations.
The role of opioids as an environmental teratogen specifi-
cally in the development of CL/P has been studied for a number
of years. Saxén (1975a) explored the link between maternal
influenza, drug consumption and oral clefts in 599 children
with oral clefts and matched controls. The conclusion was
reached that the drugs, rather than the influenza, were terato-
genic agents. In a second study (Saxén, 1975b), associations
between drug consumption during pregnancy and children with
oral clefts revealed an association between drug use and the
birth of children with cleft lip with or without cleft palate.
Bracken and Holford (1981) investigated the exposure to pre-
scribed drugs in pregnancy and the association with congenital
malformations in a case–control study involving 1427 identi-
fied infants and 3001 control cases, respectively. The authors
posited that an association existed between prenatal fetal opioid
exposure (OE) and CL/P. Bracken and Holford (1981) called
for further research on the impact of simultaneous exposure to
environmental factors and interactions of the many different
substances to which the maternofetal unit could be exposed.
In another cohort study by Thomas (1995) on substance
abusing mothers and CL/P in Australia over a 10-year period,
it was determined that there was a ten-fold increase in CL/P in
comparison to general incidence figures and a very high occur-
rence of Sudden Infant Death Syndrome. Thomas (1995)
pointed out that although there was no evidence that narcotic
drugs alone were teratogenic, other environmental factors such
as low socio-economic status, low levels of maternal education,
suboptimal nutritional status of the mothers, and polysubstance
use could lead to an increased risk of structural anomalies.
A retrospective cohort study was conducted by Meyer et al.
(2015) on 609 opioid dependent pregnant women treated with
methadone (n ¼ 248) versus buprenorphine (n ¼ 361) during
pregnancy. Two infants had congenital malformations: 1 infant
was born with an absent hand to a mother who conceived while
being treated with methadone, and 1 infant was born with an
isolated cleft palate to a mother who conceived while being
treated with buprenorphine.
Recently Lind et al. (2017) conducted a systematic review to
evaluate the association between prenatal opioid use and con-
genital malformations. Of the 68 studies included in the review,
17 studies (10 of 12 case control, and 7 of 18 cohort studies)
documented statistically significant positive associations
between prenatal opioid use and congenital malformations.
Among the 10 case–control studies, clefts and ventricular/atrial
septal defects were the most frequently reported specific mal-
formations. However, Lind et al. (2017) concluded that uncer-
tainty remains regarding the teratogenicity of opioids. Results
were therefore inconclusive regarding the impact specifically
of OE during pregnancy and the impact on the development of
CL/P.
Most recently 2 very large retrospective cohort studies were
conducted by Mullens et al. (2019) and Danis et al. (2020) to
better understand the association between NOWS and CL/P.
Mullens et al. (2019) analyzed 11 599 live hospital births in
West Virginia University’s tertiary care center between 2013
and 2017. Findings indicated a higher prevalence of CL/P in
infants with NOWS (6.79 per 1000 live births) as compared to
1.63 per 1000 live births in the general population. Isolated
cleft palate (CP) and isolated cleft lip (CL) were significantly
more prevalent in NOWS patients compared to the general
population and were associated with in-utero OE (Mullens
et al., 2019). Danis et al. (2020) used the 2016 nationwide Kid’s
Inpatient Database to evaluate the associations between NOWS
and CL/P in the United States. The data set consisted of 3 769
272 weighted in-hospital births. Danis et al. also determined an
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association between NOWS and CL/P, specifically for isolated
CP, suggesting that prenatal exposure to opioids may be an
environmental risk factor in the development of CL/P. Both
these studies call for further research to better characterize this
relationship, which is not yet well understood despite the grow-
ing body of research.
Rationale and Hypotheses
Motivating the current study, an early research project on
Speech-Language Pathology services for infants with NOWS
in a Neonatal Intensive Care Unit of the local health system
revealed a surprising number of infants with NOWS and CL/P
(Bowman et al., 2018). At about the same time, clinical faculty
anecdotally reported an increase in infants with prenatal OE or
NOWS and submucous clefts at the ETSU Speech-Language
Hearing Clinic. Then, the eye-opening publication of Mullens
et al. (2019) appeared. Shortly after its publication, we gained
access to a large local database that included infants with
NOWS, prompting consideration of a population-based repli-
cation study. While engaged in data analysis in our study,
Danis et al. (2020) published their research and we realized
we could extend the findings of the Mullens et al. (2019) and
Danis et al. (2020) studies by more specifically describing the
sample in 3 ways. First, we defined a novel experimental
group: infants prenatally opioid exposed but without NOWS.
Second, we confirmed that infants coded as NOWS actually
met diagnostic criteria for NOWS. Finally, we focused on
infants whose primary prenatal drug exposure was to opioids.
We hypothesized that across CL/P categories, infants with
NOWS would have prevalence rates and odds ratios higher
than those not exposed to opioids (Mullens et al., 2019; Danis
et al., 2020). We had no predictions about infants prenatally
opioid exposed but without NOWS.
Methods
Research Ethics
The East Tennessee State University Medical Institutional
Review Board reviewed the study protocol, granted ethics
approval, and ensured that Health Insurance Portability and
Accountability Act regulations were followed. The researchers
received only deidentified information.
Research Design
This study represents an exploratory, retrospective, cohort
design to examine the prevalence, odds-ratios, demographic,
and potentially contributing factors of CL/P in infants with OE
or with NOWS.
Population
The Ballad Health System chart review database, which houses
electronic health records from the system’s delivery hospitals
provided the information used in this study. Ballad Health
System is an Appalachian regional health care organization that
serves communities in Northeast Tennessee, Southwest
Virginia, and Southeast Kentucky. For this retrospective study,
the extracted database included all newborn records (N ¼ 18
728) from 5-year period (July 1, 2011-June 30, 2016). Of these,
16 597 charts were sufficiently complete for the purposes of the
study. Of these, 16 090 infants who were not exposed to drugs,
including opioids, comprised the reference group for the study
sample.
Study Sample
Infants with NOWS. From this initial database, the medical
records of all infants (n ¼ 507) who received an International
Classification of Disease, Ninth Revision (ICD-9) (779.5) or
International Classification of Disease, Tenth Revision (ICD-
10) code (P96.1) for NOWS, received a detailed review to
confirm prenatal OE and a criterion-based diagnosis of NOWS.
Prenatal OE was determined by either a positive maternal urine
drug screen and/or report at delivery. The NOWS criteria for
pharmacological treatment used in the Ballad Health System
was 2 consecutive Modified Finnegan (Jansson et al., 2009)
scores of 10. Of the original 507 infants receiving a NOWS
ICD code, 45 were excluded because their drug exposure did
not include opioids or their exposure to opioids was postnatal,
rather than prenatal. Thus, the detailed review resulted in iden-
tification of 462 infants who were opioid exposed. Of these
infants, 294 were identified with NOWS and 168 were not. All
infants opioid exposed received an additional code to indicate
their status. This resulted in 2 mutually exclusive opioid
exposed groups: infants without NOWS and infants with
NOWS.
This study sample is unique in the vigilance taken to define
the sample. First, it included only infants whose prenatal drug
exposure involved opioids. Second, it included only infants
prenatally opioid exposed. It did not include infants who expe-
rienced withdrawal in response to postnatal opioid exposure as
a result of surgeries (eg, for heart defects, necrotizing entero-
colitis, etc). Finally, infants were categorized based on objec-
tive criteria recorded in the medical record and not on ICD
codes alone.
Infants with CL/P. Because the time of record collection spanned
the transition from use of ICD-9 to ICD-10, both sets of codes
were used to identify the presence of CP, CL, or CLP (see
Table 1). In total, the database included 30 infants with CL/
P: 22 who were not opioid exposed (NOE); 6 who were opioid
exposed but not NOWS; and 2 who were opioid exposed with
NOWS.
Potential Confounding Variables
To examine whether it was possible that opioids served as a
potential teratogenic agent, other potentially confounding vari-
ables available in the database that have known links to CL/P
were examined. These fell into 4 categories: demographic
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variables, birth-related variables, maternal health variables,
and other drug exposures. The variables related to these cate-
gories and available in the database can be seen in Table 2.
Data Analysis
Data analysis was conducted to test the hypotheses. Associations
between NOWS and CL/P were quantified by calculating preva-
lence rates and odds ratios for the reference and study groups:
(1) infants not prenatally opioid exposed (NOE); (2) infants
opioid exposed, not NOWS (OE); and (3) infants with NOWS
requiring pharmacological care (NOWS). Odds ratios were deter-
mined using the MEDCALC© online statistical program, version
19.4, Odds Ratio Calculator (Altman, 1991; Sheskin, 2004, as
cited in MEDCALC©). As no infants with NOWS had CL, 0.5
was added to all cells (Deeks and Higgins, 2010; Pagano and
Gauvreau, 2000, as cited in MEDCALC©).
Associations between the reference group (NOE) and the
opioid exposed groups (OE and NOWS) with other potential
confounding variables were compared using Fisher exact test,
1-tailed, for categorical data, and t-tests for independent sam-
ples with continuous data (Hays, 1994; Kim, 2017) using
STATISTICA© data analysis software system (2009).
Results
Examination of the database revealed that CL/P was present in
all groups: NOE, OE, and NOWS.
Population, Sample, and Prevalence
The prevalence of CL/P was 1.37, 35.71, and 6.80 per 1000 live
births in the NOE, OE, and NOWS groups, respectively as
shown in Figure 1.
Odds Ratios
Comparison of infants with OE to the NOE reference group
revealed significantly increased odds for CL/P, CP, CL, and
CLP (see Table 2). For infants with OE, odds ratios ranged
from 19.26 to 41.8 (all Ps < .008). Furthermore, the odds of
infants with OE were higher for each type of CL/P than were
those of infants with NOWS in comparison to the infants with
NOE. The odds ratio for infants with NOWS in comparison
with infants with NOE were significant for CL/P and CP (both
Ps < .03) but not for or CL and CLP (both Ps > .11).
Infant Demographic and Birth Variables
The infants with OE and those with NOWS did not differ
significantly from the infants in the NOE group on any of the
demographic or birth variables examined, with the exception of
length of stay in the hospital. See Table 3 for descriptive infor-
mation. The OE and NOWS groups did not differ from the
NOE group in sex, race, insurance type (all Fisher exact Ps >
.60). Compared to the infants with NOE, the infants with OE
(all ts(1, 26) > 0.19; all Ps > .19) and infants with NOWS (all
ts(1, 22) > 0.20; all Ps > .05) did not differ in gestation (wks),
birth weight (g), birth length (in), Apgar scores at 1 and 5
minutes. The infants with NOWS, however, had significantly
longer hospital stays, than the infants with NOE (t(1,22) ¼
5.86; P < .0001). The infants with OE showed a similar trend,
but the difference in length of stay did not quite reach signifi-
cance (t(1,26) ¼ 2.03; P ¼ .053).
Maternal Demographics and Health
The mothers of infants with OE and those with NOWS did not
differ significantly from the mothers of infants in the NOE
group on any of the demographic or birth variables examined,
with the exception of maternal weight at delivery and mental
health disorders. See Table 3 for descriptive information. Com-
pared to the mothers of the NOE group, those of the OE group
(all ts(1, 26) > 0.19; all Ps > .60) and NOWS group (all ts(1, 22)
> 1.0; all Ps > .16) did not differ in age at delivery or parity
(ie, number of births of greater than 24 weeks gestational age).
While greater proportions of the mothers of infants with OE or
Table 2. Odds Ratios for All Types of CL/P for the OE and NOWS
Groups Compared to NOE Group.
Cleft type n Odds ratio 95% CI z P
Infants with OE
CL/P 6 27.05 10.82-67.60 7.057 <.0001a
CL 3 41.81 10.72-163.10 5.375 <.0001a
CP 1 19.26 2.24-165.78 2.694 .0071a
CLP 2 19.37 4.21-89.10 3.807 .0001a
Infants with NOWS
CL/P 2 5.00 1.17-21.37 2.173 .03a
CL 0 3.64 0.21-63.89 0.884 .38
CP 1 10.98 1.28-94.27 2.184 .029a
CLP 1 5.49 0.70-43.01 1.621 .105
Abbreviations: CL, cleft lip only; CLP, cleft lip and palate; CL/P, cleft lip and/or
cleft palate; CI, confidence interval; CP, cleft palate only; n, population size;
NOWS, neonatal opioid withdrawal syndrome; OE, opioid exposed; p, statis-
tical probability; z, standard deviation.
aSignificant at P < .05.
Table 1. ICD-9 and ICD-10 Codes Used to Identify Presence of CP, CL, and CLP.
Diagnoses ICD-9 ICD-10
CP 749.00, 749.01, 749.02, 749.03, 749.04 Q35.1, Q35.3, Q35.5, Q35.9
CL 749.10, 749.11, 749.12, 749.13, 749.14 Q36.0, Q36.1, Q36.9,
CLP 749.20, 749.21, 749.22, 749.23, 749.24, 749.25 Q37.0, Q37.1 Q37.2, Q37.3, Q37.4, Q37.5, Q37.8, Q37.9
Abbreviations: CL, cleft lip; CLP, cleft lip and palate; CP, cleft palate only; ICD, International Classification of Disease.
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Figure 1. Population and sample sizes, and prevalence rates of CL/P.
Table 3. Occurrence of Demographic and Contributing Factors in NOE, OE, and NOWS Groups With CL/P.
Categories
NOE OE NOWS
n %, M (SD) n %, M (SD) n %, M (SD)
Demographic
Infant sex (male) 14 63.6% 4 66.7% 1 50%
Infant race (white) 21 95.5% 6 100% 2 100%
Public insurance 10 45.5% 3 50% 1 50%
Maternal age (yrs) 22 25.6 (5.0) 6 25.2 (3.3) 2 29.5 (5.0)
Single 9 40.1% 5 83.3% 2 100%
Birth
Gestation (wks.) 22 39.0 (1.1) 6 39.7 (1.1) 2 39.9 (0.8)
Birth weight (g) 22 3370.7 (497.1) 6 3416.5 (541.5) 2 3654.5 (1075.5)
Birth length (in) 22 20.1 (1.0) 6 20.5 (1.2) 2 21 (1.4)
Apgar 1 min 21 7.9 (0.8) 6 7.8 (0.8) 1 8.0 (0.0)
Apgar 5 min 21 8.9 (0.3) 6 9.0 (0.0) 1 9.0 (0.0)
Length of stay (d) 22 2.6 (1.2) 6 1.5 (1.2) 2 12.0 (8.5)
Maternal health
Parity 22 0.8 (0.7) 6 1.0 (1.1) 2 1.5 (0.7)
Delivery Wt. (lbs.) 19 190.3 (36.0) 6 171.8 (36.1) 2 251.0 (72.1)
Prenatal care (yes) 22 100% 6 100% 2 100%
Malnutrition (yes) 5 22.7% 1 16.7% 1 50%
Obesity (yes) 5 22.7% 0 0% 1 50%
Mental health (yes) 2 9.09% 4 66.7% 0 0%
Drug exposures
Alcohol 1 4.5% 0 0% 0 0%
Nicotine 8 36.4% 2 33.3% 1 50%
Marijuana 1 4.5% 2 33.3% 0 0%
Abbreviations: d, days; g, grams; in, inches; lbs, pounds; M, mean; min, minutes; n, sample size; NOE, no opioid exposure; NOWS, neonatal opioid withdrawal
syndrome; OE, opioid exposure; SD, standard deviation; wks., weeks.
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NOWS were single compared to mothers of infants with NOE,
the differences were not significant (all Fisher exact Ps > .07).
The mothers of infants with NOWS weighed significantly
more than those of infants with NOE (t(1,22) ¼ 2.11;
P ¼ .048). The weights of the mothers of the OE group did
not significantly differ from those of the NOE group (t(1,26) ¼
1.10; P¼ .28). A significantly greater proportion of mothers of
infants with OE experienced mental health disorders than those
of infants with NOE (P ¼ .01). The proportions in the NOWS
and OE groups did not differ (P ¼ .84). The proportion of
mothers in the OE and NOWS groups did not differ signifi-
cantly in malnutrition or obesity (all Fisher exact Ps > .25)
when compared to the mothers of the NOE group.
Exposure to Other Substances
There were no positive urine drug screen results or maternal
self-report of benzodiazepines, cocaine, barbiturates, ampheta-
mines, and codeine. The proportions of mothers of infants with
OE or NOWS did not differ from those of infants with NOE in
use of alcohol, nicotine, or marijuana (all Fisher exact Ps >
.10).
Trimester of Opioid Use
Of the 2 mothers of infants with NOWS, one reported she used
opioids throughout the pregnancy, while the other reported she
used only during the third trimester. Of the 6 mothers of infants
with OE, 4 reported opioid use during the first trimester at least.
More specifically, 2 mothers reported opioid use throughout
the pregnancy, 1 reported use only during the first trimester,
1 reported use only during the first and second trimesters, and
2 reported use only during the third trimester.
Discussion
Prevalence of CL/P
The prevalence of CL/P in this study’s comparison sample was
generally representative of those reported more broadly and in
Mullens et al. (2019) and Danis et al. (2020). The prevalence
per 1000 live births of CL/P in the NOE comparison group at
1.37 was almost identical to that of Danis et al. (2020) at 1.35.
It was somewhat higher than the US national figure of 1.06
(National Institute on Dental and Craniofacial Research, nd)
and the rates in Tennessee and Virginia at 1.10 and 1.05,
respectively (National Birth Effects Prevention Network,
2010). This study’s prevalence rate was lower than that
reported by Mullens et al. (2019) at 1.63 and the international
rate range at 1.42 to 2.00 (World Health Organization, 2001).
In the NOWS groups, the prevalence of CL/P per 1000 in
this study at 6.80 was virtually identical to that of Mullins et al.
(2019) at 6.79. Both of these prevalence numbers were much
higher than that reported by Danis et al. (2020) at 3.13, most
likely due to the national nature of their study and large
population.
The similarities of our data for infants in the NOE and
NOWS groups to that of other reports and studies gives initial
credence to the surprisingly high prevalence of CL/P in the
newly introduced sample of infants with OE. They showed a
prevalence rate of 35.71 per 1000 live births. However, this
remarkable result needs verification through replication.
Odds Ratios of CL/P
Infants with NOWS. In comparison the infants with NOE, those
with NOWS had a significantly higher odds for CL/P and CP
(5.00 and 10.98, respectively) but did not differ in their like-
lihood of CL and CLP. These findings of significance mirror
those of Danis et al. (2020) though they report lower odds for
CL/P and CP (2.33 and 4.97, respectively). Mullens et al.
(2019) also found significantly higher odds ratios for CL/P
(4.18), but not for CP or CLP. However, they uniquely found
an increased likelihood of CL, with an odds ratio of 5.92.
The differences in the odds ratios and patterns of significant
differences for infants with NOWS may be related to a number
of factors. Danis et al. (2020) ascribed the differences to sample
demographics (ie, race and sex), sample size, and incidence of
NOWS in different states across the US. This view is supported
by WHO (2001), which attributes the range of prevalence to the
considerable variance across geographical regions and ethnic
groupings.
Another source of difference may be attributed to the use of
different criteria across hospital systems in identification of
NOWS. There is no commonly accepted protocol or standard
endorsed by the American Medical Association for nonphar-
macological or pharmacological intervention and monitoring
of symptoms to aid diagnosis of NOWS (Kocherlakota, 2014).
Also, this study made significant efforts to accurately identify
infants with NOWS who received pharmacological interven-
tion and those prenatally opioid exposed who did not receive
pharmacological intervention and may or may not have had
NOWS. This resulted in 45 infants initially coded as having
NOWS being excluded. Furthermore, we divided the original
NOWS sample into 2 distinct groups, NOWS and OE, based on
a deep review of the infants’ medical records. Thus, the infants
with NOWS in our study may not have included some of the
infants identified as NOWS in the studies of Mullens et al.
(2019) and Danis et al. (2020). Furthermore, it may be that
some of the infants identified as OE in our study appeared in
their studies as NOWS. This may have contributed to
differences in odds ratios across studies. Irrespective of classi-
fication, all 3 studies confirmed an association between NOWS
and CL/P.
Infants with OE. The inclusion of infants with OE in this study
provides new data about the likely teratogenicity of opioids for
CL/P. This group showed significantly higher and concerning
odds ratios for CL/P (27.05), CL (41.81), CP (19.26), and CLP
(19.37) in comparison to infants with NOE. It appears that the
current study corroborates previous studies (eg, Saxén, 1975a;
Saxén, 1975b; Bracken and Holfrod, 1981; Thomas, 1995;
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Meyer et al., 2015) that pointed to the association of fetal OE
and CL/P. Our data further specifies that in utero exposure to
opioids is a contributory environmental risk factor in CL/P
whether or not the infants show withdrawal signs or require
pharmacological intervention.
Other Potentially Confounding Variables
There were few differences in the demographic, maternal
health, birth, or drug exposures variables that we explored.
Among the few differences, the significantly longer length of
stay in the hospital for infants with NOWS than those with
NOE reflects the complexity of their care and recovery from
withdrawal symptoms (Kocherlakota, 2014; Patrick et al.,
2015). The mothers of infants with NOWS weighed signifi-
cantly more and a significantly greater proportion of mothers
of infants with OE experienced mental health disorders than
those of infants with NOE.
The demographic and health conditions of mothers and
infants in this study reflect the health disparities endemic in
this rural Appalachia region (Erwin et al., 2017). Thus, with
respect to confounding variables, the mothers and infants in the
NOE group may not be as different from those in the OE and
NOWS groups as they might be in other areas of the nation.
The presentation of confounding variables in the NOE, OE, and
NOWS groups did not differ. Thus, the potential unique con-
tribution of prenatal exposure to opioids as the primary envi-
ronmental difference between the groups is revealed.
Limitations
Like Mullens et al. (2019), our sample was limited to a specific
geographical region in Appalachia, in contrast to the national
database utilized by Danis et al. (2020). Also, given the rela-
tively small numbers of infants in the NOE, OE, and NOWS
groups, the current study lacked the power for confidently
detecting differences in demographic and contributing factors
between the NOWS group and the NOE and OE groups.
Furthermore, the retrospective nature of the data prevented
capture of a full spectrum of other potential confounding
variables necessary for investigation of the multifactorial
nature of CL/P.
Future Directions
Now that there are similar findings from 3 large scale studies of
the association between prenatal OE and CL/P, consideration
of a theoretical view is warranted. Both Mullens et al. (2019)
and Danis et al. (2020) emphasized the need for better under-
standing of the environmental risk factors for CL/P in the
NOWS population. However, the likelihood of isolating risk
factors individually is challenging, given the complexity of the
population (Kocherlakota, 2014; Bailey et al., 2017). In the
future, researchers may want to consider approaching this prob-
lem holistically. The Multifactorial Threshold (MF/T) model as
applied to CL/P offers this opportunity (Zajac and Vallino,
2017). The MF/T model postulates that when an individual has
a predisposition toward a given disorder, and is exposed to
certain environmental conditions, the disorder will present
itself (Zajac and Vallino, 2017). For example, prenatal expo-
sure to opioids along with other adverse environmental factors,
combined with a genetic susceptibility of the fetus, may push
the fetus over the threshold and lead to a CL/P.
Conclusions
This study clearly indicated that for infants prenatally exposed
to opioids there is increased prevalence and likelihood of hav-
ing CL/P. Together with the findings of the recent large-scale
studies of Mullens et al. (2019) and Danis et al. (2020), it is
clear that opioids are a substantial environmental risk factor for
CL/P, particularly considering the opioid crisis in the US.
Acknowledgments
The authors would like to thank the members of the interprofessional
NAS Working Group who shared their scholarly insights and literature
about NOWS and its neurodevelopmental outcomes. We gratefully
acknowledge Dr Beth Bailey for her help identifying infants with
CL/P within the database and the M.S. SLP students who contributed
to the initial phase of this study.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to
the research, authorship, and/or publication of this article.
Funding
The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: The cre-
ation of the database was financially supported in part by the Junior




Bailey BA, Wood D, Clements AD, Proctor-Williams K, Boynewicz K,
Trivette C, Justice N. Polydrug use and other risk factors among
women receiving MAT during pregnancy: challenges for research on
health and developmental effects in infancy and beyond. Poster pre-
sented at: The Teratology Society 57th Annual Meeting; 2017; Denver,
CO.
Barfield W. The Problem of Neonatal Abstinence Syndrome. Centers
for Disease Control and Prevention. 2016. Accessed March 15,
2019. https://www.cdc.gov/cdcgrandrounds/pdf/archives/2016/
august2016.pdf
Bateman BT, Hernandez-Diaz S, Rathmell JP, Seeger JD, Doherty M,
Fischer MA, Huybrechts KF. Patterns of opioid utilization in preg-
nancy in a large cohort of commercial insurance beneficiaries in
the United States. J Am Soc Anesthesiol. 2014;120(5):1216-1224.
doi:10.1097/ALN.0000000000000172
Benninger KL, Borghese T, Kovalcik JB, Moore-Clingenpeel M, Isler
C, Bonachea EM, Maitre NL. Prenatal exposures are associated
Proctor-Williams and Louw 7
with worse neurodevelopmental outcomes in infants with neonatal
opioid withdrawal syndrome. Front Pediatr. 2020;8(8):462zx.
Birth Defects State Profile—Tennessee. National birth defects preven-
tion network. January 2010. Accessed October 18, 2019. https://
www.nbdpn.org/docs/TN_2010_C.pdf
Bowman CH, Horstman E, Nava-Sifuentes M, Sanders K, Townsend
S, Carder N, Proctor-Williams K. Infants with neonatal abstinence
syndrome: who receives SLP services in the NICU? Poster pre-
sented at: the American Speech-Language-Hearing Association
Convention; November 15, 2018; Boston, MA.
Bracken MB, Holford TL. Exposure to prescribed drugs in pregnancy
and association with congenital malformations. Obstetr Gynecol.
1981;58(3):336-344.
Broussard CS, Rasmussen SA, Reefhuis J, Friedman JM, Jann MW,
Riehle-Colarusso T, Honein MA. Maternal treatment with opioid
analgesics and risk for birth defects. Am J Obstetr Gynecol. 2011;
204(4):314, e1-11.
Centers for Disease Control and Prevention. Prescription painkiller
overdoses: a growing epidemic, especially among women. 2013.
Accessed October 18, 2019. https://www.cdc.gov/vitalsigns/pre
scriptionpainkilleroverdoses/index.html
Danis DO, Bachrach K, Piraquive J, Marston AP, Levi JR. Cleft lip
and palate in newborns diagnosed with neonatal abstinence syn-
drome. Otolaryngol Head Neck Surg. 2020;163(1):1-7. doi:10.
1177/0194599820944899
Davies H, Gilbert R, Johnson K, Petersen I, Nazareth I, O’Donnell M,
Guttmann A, Gonzalez-Izquierdo A. Neonatal drug withdrawal
syndrome: cross-country comparison using hospital administrative
data in England, the USA, Western Australia and Ontario, Canada.
Arch Dis Child Fetal Neonatal Ed. 2016;101(1):26-30. doi:10.
1136/archdischild-2015-308948
Desai RJ, Hernandez-Diaz S, Bateman BT, Huybrechts KF. Increase
in prescription opioid use during pregnancy among Medicaid-
enrolled women. Obstetri Gynecol. 2014;123(5):997-1002. doi:
10.1097/aog.0000000000000208
Erwin PC, Lindley L, Meschke LL, Ehrlich SF. Neonatal abstinence
syndrome in East Tennessee: characteristics and risk factors
among mothers and infants in one area of Appalachia. J Health
Care Poor Underserved. 2017;28(4):1393.
Fill MMA, Miller AM, Wilkinson RH, Warren MD, Dunn JR, Schaffner
W, Jones TF. Educational disabilities among children born with neo-
natal abstinence syndrome. Pediatrics. 2018;142(3):e20180562.
Finnegan LP, Connaughthon JF, Kron RE, Emich JP. Neonatal absti-
nence syndrome: assessment and management. Addict Dis. 1975;
2(1-2);141-158.
Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescrip-
tion opioid use, misuse, and use disorders in U.S adults: 2015
national survey on drug use and health. Ann Intern Med. 2017;
167(5):293-301. doi:10.7326/m17-0865
Hays WL. Statistics. 5th ed. Harcourt Brace College Publishers; 1994.
Jansson LM, Velez M, Harrow C. The opioid exposed newborn:
assessment and pharmacologic management. J Opioid Manage.
2009;5(1):47-55.
Jones HE, O’Grady KE, Johnson RE, Velez M, Jansson LM. Infant
neurobehavior following prenatal exposure to methadone or bupre-
norphine: results from the neonatal intensive care unit network
neurobehavioral scale. Subst Use Misuse. 2010;45(13):
2244-2257. doi:10.3109/10826084.2010.484474
Kim HY.Statistical notes for clinical researchers: Chi-squared test and
Fisher’s exact test. Restor Dent Endod. 2017;42(2):152. doi:10.
5395/rde.2017.42.2.152
Ko JY, Patrick SW, Tong VT, Patel R, Lind JN, Barfield WD. Inci-
dence of neonatal abstinence syndrome—28 states, 1999-2013.
MMWR Morb Mortal Wkly Rep. 2016;65(31):799-802. doi:10.
15585/mmwr.mm6531a2
Kocherlakota P. Neonatal abstinence syndrome. Pediatrics. 2014;
134(2):e547-e561. doi:10.1542/peds.2013-3524
Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL, Clark
TW, Alexander GC. The prescription opioid and heroin crisis: a
public health approach to an epidemic of addiction. Ann Rev Public
Health. 2015;36(1):559-574. doi:10.1146/annurev-publhealth-
031914-122957
Lind JN, Interrante JD, Ailes EC, Gilboa SM, Khan S, Frey MT,
Dawson AP, Honein MA, Dowling NF, Razzaghi H, et al. Maternal
use of opioids during pregnancy and congenital malformations: a
systematic review. Pediatrics. 2017;139(6):1-25. doi:10.1542/
peds.2016-4131
McQueen K, Murphy-Oikonen J. Neonatal abstinence syndrome. New
Engl J Med. 2016;375(25):2468-2479. doi:10.1056/nejmra1600879
MEDCALC. MedCalc for Windows (version 19.4). MecCalc Software.
2020. Accessed October 13, 2020. https://www.medcalc.org/calc/
odds_ratio.php
Meyer MC, Johnston A, Crocker A, Heil S. Methadone and buprenor-
phine for opioid dependence during pregnancy. J Addict Med.
2015;9(2):81-86. doi:10.1097/ADM.0000000000000092
Mullens CL, McCulloch IL, Hardy KM, Matthews RE, Mason AC.
Associations between orofacial clefting and neonatal abstienece
syndrome. Plast Reconstr Surgery Glob Open. 2019;7(1):e2095.
doi:10.1097/GOX.0000000000002095
National Institute on Dental and Craniofacial Research. Prevalence of
cleft lip and palate. Accessed November 19, 2020. https://www.
nidcr.nih.gov/research/data-statistics/craniofacial-birth-defects/
prevalence
National Institute on Drug Abuse. Dramatic increases in maternal
opioid use and neonatal abstinence syndrome. 2019. Accessed
November 19, 2020. https://www.drugabuse.gov/drug-topics/
trends-statistics/infographics/dramatic-increases-in-maternal-
opioid-use-neonatal-abstinence-syndrome
National Institute on Drug Abuse. Monitoring the future 2019 survey
results: overall findings. 2016. Accessed November 19, 2020.
https://www.drugabuse.gov/related-topics/trends-statistics/moni
toring-future
Oei JL, Melhuish E, Uebel H, Azzam N, Breen C, Burns L, Hilder L,
Bajuk B, Abdel-Latif ME, Ward M, et al. Neonatal abstinence syn-
drome and high school performance. Pediatrics. 2017;139(2):1-10.
Patrick SW, Barfield WD, Poindexter BB. Neonatal opioid withdrawal
syndrome. Pediatrics. 2020;146(5):e2020029074. doi:10.1542/
peds.2020-029074
Patrick SW, Davis MM, Lehmann CU, Cooper WO. Increasing inci-
dence and geographic distribution of neonatal abstinence syn-
drome: United States 2009 to 2012. J Perinatol. 2015;35(8):
650-655. doi:10.1038/jp.2015.63
8 The Cleft Palate-Craniofacial Journal XX(X)
Raval A, Pan X, Sambamoorthi U. FDA CDX category medication
use during pregnancy in the United States. Value Health. 2014;
17(7):A519. doi:10.1016/j.jval.2014.08.1618
Saxén I. The association between maternal influenza, drug consump-
tion and oral clefts. Acta Odontologica Scandinavica. 1975a;33(5):
259-267. doi:10.3109/00016357509004631
Saxén I. Associations between oral clefts and drugs taken during
pregnancy. Int J Epidemiol. 1975b;4(1):37-44. doi:10.1093/ije/4.
1.37
StatSoft Inc. STATISTICA Data Analysis Software System (version 9.0).
2009. www.statsoft.com
Thomas DB. Cleft palate: mortality and morbidity in infants of substance
abusing mothers. J Pediatr Child Health. 1995;31(5):457-460.
World Health Organization. (2001) Global Registry and Database on
Craniofacial Anomalies: Report of a WHO Registry Meeting on
Craniofacial Anomalies. Bauru, Brazil: World Health
Organization.
Wu LT, Zhu H, Swartz MS. Treatment utilization among persons with
opioid use disorder in the United States. Drug Alcohol Depend.
2016;169:117-127.
Yang T, Walker MC, Krewski D, Yang Q, Nimrod C, Garner P, Fraser
W, Olatunbosun O, Wen SW. Maternal characteristics associated
with pregnancy exposure to FDA category C, D, and X drugs in a
Canadian population. Pharmacoepidemiol Drug Saf. 2008;17(3):
270-277. doi:10.1002/pds.1538
Yazdy MM, Desai RJ, Brogly SB. Prescription opioids in pregnancy
and birth outcomes: a review of the literature. J Pediatr Genet.
2015;4(2):56-70.
Zajac D, Vallino L. Evaluation and management of cleft palate. Devel-
opmental Perspective. Plural Publishing; 2017.
Proctor-Williams and Louw 9
